Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,641.49
    -1,637.88 (-3.26%)
     
  • CMC Crypto 200

    1,261.32
    -96.68 (-7.12%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Should Pfizer Shareholders Sell Their Viatris Stock?

Should Pfizer Shareholders Sell Their Viatris Stock?

Pfizer's (NYSE: PFE) long-awaited deal is finally done. The transaction created a new entity, Viatris (NASDAQ: VTRS), that's a leader in branded and generic drugs and biosimilars. If you owned Pfizer shares prior to the close of the deal, you now also own roughly 0.124079 shares of Viatris for every one share of Pfizer common stock held.